Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
March 30, 2022 07:00 ET
|
Replimune Group Inc
RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive initial data in patients with...
Replimune to Host Virtual Investor Event on March 30, 2022
March 21, 2022 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 11, 2022 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
February 03, 2022 08:00 ET
|
Replimune Group Inc
Data expected to be presented at an investor event in March 2022: Data updates from the completed RP1 IGNYTE cohorts in anti-PD1 naïve non-melanoma skin cancer (NMSC) and anti-PD1 naïve and failed...
Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors
January 31, 2022 16:01 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones
January 10, 2022 07:00 ET
|
Replimune Group Inc
CERPASS clinical trial with RP1 in CSCC on track to complete enrollment mid-year with the primary analysis trigger six months thereafter IGNYTE anti-PD1 failed melanoma, evaluating RP1 in combination...
Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Appoints Christy Oliger to its Board of Directors
December 02, 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy...
Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
November 12, 2021 07:00 ET
|
Replimune Group Inc
RP2 data demonstrates deep and durable responses in difficult to treat cancers both as monotherapy and in combination with Opdivo® (nivolumab) Initiated Phase 1 expansion of RP2 in combination...
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
November 04, 2021 08:00 ET
|
Replimune Group Inc
RP1; Full patient accrual in CERPASS registration-directed clinical trial continues to be expected in mid-year 2022 with the primary data trigger expected in late 2022. Interim data in the IGNYTE...